| Literature DB >> 28463966 |
Corina S Rueegg1,2, Micòl E Gianinazzi3, Gisela Michel1,3, Marcel Zwahlen1, Nicolas X von der Weid4, Claudia E Kuehni1,5.
Abstract
PURPOSE: This is the first study to quantify potential nonresponse bias in a childhood cancer survivor questionnaire survey. We describe early and late responders and nonresponders, and estimate nonresponse bias in a nationwide questionnaire survey of survivors.Entities:
Mesh:
Year: 2017 PMID: 28463966 PMCID: PMC5413049 DOI: 10.1371/journal.pone.0176442
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study design and response behavior in the Swiss Childhood Cancer Survivor Study.
The different procedures of the Swiss Childhood Cancer Survivor Study and the number of participants in each step of the study.
Characteristics of survivors by type of response; risk ratios from univariable multinomial logistic regression models.
| Total (n = 2328) | Early responders | Late responders | Non-responders | RR | 95% CI | RR | 95% CI | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | p-value | |||||||
| <0.001 | |||||||||||||||
| Male | 1315 | 56.5 | 455 | 34.6 | 396 | 30.1 | 464 | 35.3 | 1 | 1 | |||||
| Female | 1013 | 43.5 | 475 | 46.9 | 275 | 27.1 | 263 | 26.0 | 1.84 | 1.51–2.43 | 1.23 | 0.99–1.52 | |||
| <0.001 | |||||||||||||||
| < 20 | 468 | 20.1 | 179 | 38,2 | 116 | 24,8 | 173 | 37,0 | 1 | 1 | |||||
| 20–29 | 1144 | 49.1 | 424 | 37,1 | 365 | 31,9 | 355 | 31,0 | 1.15 | 0.90–1.49 | 1.53 | 1.16–2.02 | |||
| 30–39 | 564 | 24.2 | 258 | 45,7 | 151 | 26,8 | 155 | 27,5 | 1.61 | 1.21–2.15 | 1.45 | 1.05–2.01 | |||
| ≥ 40 | 152 | 6.5 | 69 | 45,4 | 39 | 25,7 | 44 | 28,9 | 1.52 | 0.98–2.33 | 1.32 | 0.81–2.16 | |||
| 0.011 | |||||||||||||||
| German | 1684 | 72.3 | 710 | 42,2 | 469 | 27,9 | 505 | 30,0 | 1 | 1 | |||||
| French | 561 | 24.1 | 189 | 33,7 | 178 | 31,7 | 194 | 34,6 | 0.69 | 0.55–0.87 | 0.99 | 0.78–1.25 | |||
| Italian | 83 | 3.6 | 31 | 37,3 | 24 | 28,9 | 28 | 33,7 | 0.79 | 0.47–1.33 | 0.92 | 0.53–1.61 | |||
| <0.001 | |||||||||||||||
| Swiss | 2017 | 89.3 | 868 | 43,0 | 602 | 29,8 | 547 | 27,1 | 1 | 1 | |||||
| German, Austrian, French, Italian | 102 | 4.5 | 35 | 34,3 | 28 | 27,5 | 39 | 38,2 | 0.57 | 0.35–0.90 | 0.65 | 0.40–1.07 | |||
| Other | 140 | 6.2 | 26 | 18,6 | 41 | 29,3 | 73 | 52,1 | 0.22 | 0.14–0.36 | 0.51 | 0.34–0.76 | |||
| 0.754 | |||||||||||||||
| First tertile (lowest SEP) | 678 | 33.4 | 258 | 38,1 | 207 | 30,5 | 213 | 31,4 | 1 | 1 | |||||
| Second tertile | 678 | 33.4 | 278 | 41,0 | 186 | 27,4 | 214 | 31,6 | 1.07 | 0.83–1.38 | 0.89 | 0.68–1.18 | |||
| Third tertile (highest SEP) | 677 | 33.3 | 265 | 39,1 | 198 | 29,2 | 214 | 31,6 | 1.02 | 0.79–1.32 | 0.95 | 0.73–1.25 | |||
| 0.020 | |||||||||||||||
| I Leukemia | 784 | 33.7 | 343 | 43,8 | 231 | 29,5 | 210 | 26,8 | 1 | 1 | |||||
| II Lymphoma | 441 | 18.9 | 154 | 34,9 | 137 | 31,1 | 150 | 34,0 | 0.63 | 0.47–0.83 | 0.83 | 0.62–1.12 | |||
| III CNS tumor | 326 | 14.0 | 128 | 39,3 | 83 | 25,5 | 115 | 35,3 | 0.68 | 0.50–0.92 | 0.66 | 0.47–0.92 | |||
| IV Neuroblastoma | 102 | 4.4 | 41 | 40,2 | 27 | 26,5 | 34 | 33,3 | 0.74 | 0.45–1.20 | 0.72 | 0.42–1.24 | |||
| V Retinoblastoma | 57 | 2.5 | 19 | 33,3 | 18 | 31,6 | 20 | 35,1 | 0.58 | 0.30–1.11 | 0.82 | 0.42–1.59 | |||
| VI & VII Renal & hepatic tumor | 152 | 6.5 | 69 | 45,4 | 49 | 32,2 | 34 | 22,4 | 1.24 | 0.80–1.94 | 1.31 | 0.81–2.12 | |||
| VIII Bone tumor | 108 | 4.6 | 45 | 41,7 | 33 | 30,6 | 30 | 27,8 | 0.92 | 0.56–1.50 | 1.00 | 0.59–1.70 | |||
| IX Soft tissue sarcoma | 132 | 5.7 | 52 | 39,4 | 37 | 28,0 | 43 | 32,6 | 0.74 | 0.48–1.15 | 0.78 | 0.48–1.26 | |||
| X Germ cell tumor | 75 | 3.2 | 28 | 37,3 | 17 | 22,7 | 30 | 40,0 | 0.57 | 0.33–0.98 | 0.52 | 0.28–0.96 | |||
| XI & XII Other tumor | 41 | 1.7 | 10 | 24,4 | 11 | 26,8 | 20 | 48,8 | 0.31 | 0.14–0.67 | 0.50 | 0.23–1.07 | |||
| Langerhans cell histiocytosis | 110 | 4.7 | 41 | 37,3 | 28 | 25,5 | 41 | 37,3 | 0.61 | 0.38–0.98 | 0.62 | 0.37–1.04 | |||
| 0.041 | |||||||||||||||
| Surgery only | 289 | 12.6 | 110 | 38,1 | 66 | 22,8 | 113 | 39,1 | 0.69 | 0.51–0.92 | 0.56 | 0.40–0.78 | |||
| Chemotherapy | 1126 | 49.2 | 461 | 40,9 | 340 | 30,2 | 325 | 28,9 | 1 | 1 | |||||
| Radiotherapy | 778 | 34.0 | 312 | 40,1 | 232 | 29,8 | 234 | 30,1 | 0.94 | 0.75–1.17 | 0.95 | 0.75–1.20 | |||
| Bone marrow transplantation | 95 | 4.2 | 41 | 43,2 | 27 | 28,4 | 27 | 28,4 | 1.07 | 0.64–1.78 | 0.96 | 0.55–1.67 | |||
| 0.540 | |||||||||||||||
| No | 2033 | 87.3 | 819 | 40,3 | 587 | 28,9 | 627 | 30,8 | 1 | ||||||
| Yes | 295 | 12.7 | 111 | 37,6 | 84 | 28,5 | 100 | 33,9 | 0.85 | 0.64–1.14 | 0.90 | 0.66–1.22 | |||
| 0.719 | |||||||||||||||
| < 5 | 841 | 36.1 | 346 | 41,1 | 234 | 27,8 | 261 | 31,0 | 1 | 1 | |||||
| 5–9.9 | 635 | 27.3 | 241 | 38,0 | 195 | 30,7 | 199 | 31,3 | 0.91 | 0.71–1.17 | 1.09 | 0.84–1.42 | |||
| ≥ 10 | 852 | 36.6 | 343 | 40,3 | 242 | 28,4 | 267 | 31,3 | 0.97 | 0.77–1.22 | 1.01 | 0.79–1.30 | |||
| <0.001 | |||||||||||||||
| < 10 | 240 | 10.3 | 84 | 35,0 | 58 | 24,2 | 98 | 40,8 | 1 | 1 | |||||
| 10–19.9 | 1025 | 44.0 | 380 | 37,1 | 308 | 30,0 | 337 | 32,9 | 0.76 | 0.55–1.05 | 0.65 | 0.45–0.93 | |||
| 20–29.9 | 817 | 35.1 | 352 | 43,1 | 242 | 29,6 | 223 | 27,3 | 1.40 | 1.12–1.75 | 1.19 | 0.94–1.51 | |||
| ≥ 30 | 246 | 10.6 | 114 | 46,3 | 63 | 25,6 | 69 | 28,0 | 1.47 | 1.05–2.04 | 1.00 | 0.69–1.45 | |||
a Survivors responding to the first questionnaire sent (40.0%).
b Survivors responding to the first reminder letter or second reminder phone call (28.8%).
c Survivors not responding or declining participation (31.2%).
d Column percenteges are given.
e Row percentages are given.
f RRs and p-values from univariable multinomial regression models comparing early and late responders with nonresponders.
g Questionnaires were available in their mother languages (German, French, Italian).
h Chemotherapy may include surgery.
i Radiotherapy may include chemotherapy or surgery.
Abbreviations: CI, confidence interval; CNS, central nervous system; ICCC-3, International Classification of Childhood Cancer, third edition; n, number; RR, risk ratio; SEP, socioeconomic position.
Fig 2Comparison of self-reported outcomes between early responders, late responders, and a constructed complete population of the Swiss Childhood Cancer Survivor Study.
Proportions and 95% confidence intervals for typical self-reported outcomes for somatic health, medical care, mental health, and health behaviors, comparing the observed prevalence from early responders (designated with a white diamond) and all responders (designated with a grey diamond) of the SCCSS with the expected prevalence in the representative complete population (designated with a black diamond). We constructed the complete population with inverse probability of participation weights (S1 File) (22). S1 Table describes how each of the outcomes compared was assessed and classified. Abbreviations: BMI, Body Mass Index; SCCSS, Swiss Childhood Cancer Survivor Study.
Comparison of self-reported outcomes between early responders, late responders, and a representative complete population of the Swiss Childhood Cancer Survivor Study (description of the numbers presented in Fig 2).
| Early responders | All responders | Complete population | |||||
|---|---|---|---|---|---|---|---|
| % | 95% CI | % | 95% CI | % | 95% CI | ||
| Hypothyroidism | 8.2 | 6.4–9.9 | 8.4 | 7.1–9.8 | 8.6 | 7.3–10.1 | |
| Visual impairments | 6.6 | 5.0–8.2 | 7.3 | 6.0–8.6 | 7.5 | 6.3–9.0 | |
| Hearing problems | 7.1 | 5.4–8.8 | 7.4 | 6.1–8.7 | 7.4 | 6.2–8.8 | |
| Overweight (BMI >25 kg/m2) | 24.0 | 21.2–26.9 | 23.7 | 21.5–25.8 | 23.3 | 21.3–25.6 | |
| Any late effects | 38.3 | 35.2–41.5 | 35.9 | 33.5–38.3 | 35.7 | 33.3–38.2 | |
| Poor general health | 4.3 | 3.0–5.6 | 4.2 | 3.2–5.2 | 4.2 | 3.3–5.3 | |
| Regular follow-up | 33.4 | 30.3–36.6 | 33.8 | 31.4–36.2 | 35.7 | 33.2–38.2 | |
| Frequent pain medication | 11.4 | 9.4–13.4 | 11.6 | 10.0–13.1 | 11.1 | 9.6–12.7 | |
| Use alternative medicine | 31.9 | 28.9–35.0 | 30.0 | 27.7–32.3 | 28.8 | 26.6–31.1 | |
| Concentration problems | 8.2 | 6.4–10.0 | 8.7 | 7.3–10.1 | 8.6 | 7.3–10.2 | |
| Psychological distress | 14.8 | 12.4–17.2 | 15.5 | 11.8–15.2 | 13.3 | 11.7–15.2 | |
| Engagement in sports activities | 64.3 | 61.2–67.5 | 63.9 | 61.4–66.3 | 64.0 | 61.5–66.4 | |
| Current smoker | 21.7 | 19.0–24.4 | 23.0 | 20.9–25.1 | 23.1 | 21.0–25.3 | |
| In partnership or marriage | 42.3 | 39.0–45.5 | 42.9 | 40.4–45.3 | 41.2 | 38.8–43.7 | |
a Survivors who responded to the initial questionnaire (40%).
b All survivors who responded (69%).
c Constructed complete population of the SCCSS (100%).
Abbreviations: BMI, body mass index; CI, confidence interval.